A Phase II Study of Trastuzumab plus S-1 in Patients with Advanced or Recurrent HER2 positive Breast Cancer
- Conditions
- Breast cancer
- Registration Number
- JPRN-UMIN000001408
- Lead Sponsor
- Gunma Breast Clinical Conference Study Group(GBCCSG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 30
Not provided
1) Male breast cancer 2) Necessary to continue treatment with warfarin potassium 3) Severe complications [ulcer which needs blood transfusion, uncontrolled diabetes mellitus, interstitial lung disease, pulmonary fibrosis, cerebral thrombosis, cerebral hemorrhage, subarachnoid hemorrhage, ischemia attack, encephalosis, stenocardia, myocardial infarction, uncontrolled congestive heart failure or arrhythmia, intestinal tract paralysis, ileus, neurodegeneration disease, hepatic insufficiency, cirrhosis, renal insufficiency] 4) Active double cancer 5) Inflammatory breast cancer or symptomatic brain metastasis 6) Patients who have only the lesion which caught the radiation exposure 7) Patients who received previous treatment with oral fluoropyrimidines within 12 months 8) internal use of flucytosyne 9) doctors decision for excluion
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method